Presenter
Session Information
Description
The emergence of Psychedelic-assisted Therapy (PAT) as a new treatment paradigm for Canadians experiencing end-of-life distress, treatment-resistant depression, and PTSD requires understanding of both safety and efficacy. This session delivers an essential primer on PAT, focussing on psilocybin and MDMA. Through a brief discussion of current clinical research, participants will receive an overview of PAT neuroscience and pharmacotherapy. Review of the current regulatory landscape of PAT in Canada will lead to the emerging role of psychiatric pharmacists in PAT medication management.
Learning Objectives
- Discuss the general principles of Psychedelic-assisted Therapy.
- Describe the main mechanisms of action of psilocybin and MDMA.
- Outline the various Health Canada approved access routes for patients seeking psilocybin and MDMA.
- List safety concerns of psilocybin and MDMA that can be minimized with pharmacist involvement.